Teicoplanin is an antibiotic used to treat serious infections caused by staphylococci or streptococci that cannot be treated by other less toxic agents. It works by inhibiting the growth of susceptible bacteria. Common brands include Celplanin and Targocid. Teicoplanin is administered intravenously or intramuscularly and primarily excreted unchanged through urine. Potential side effects include diarrhea, vomiting, rash, and renal impairment. Renal and liver function, hematological parameters, and plasma concentration should be monitored during treatment.

1. NARASARAOPET INSTITUTE OF PHARMACEUTICAL SCIENCES
DRUG PROFILE OF
TEICOPLANIN
PRESENTED BY
SARANYA.M
13CD1T0019
IV/VI PHARM.D

2. Popular brands in india
● Celplanin 200mg,400mg
● Platico 400mg
● Targocid 200mg,400mg
● Teconin 200mg,400mg
● Tecotop 200mg,400mg
● Ticocin 200mg,400mg
● Zicoplanin 200mg 400mg

3. INTRODUCTION
● Targocid is an antibiotic. It is used to kill bacteria
responsible for infections which can occur in your
blood, bones or joints. This antibiotic is generally
used when the bacteria causing the infection are not
satisfactorily eliminated by other antibiotics (eg
penicillin) or when patients may be allergic to other
antibiotics.
● This medicine is only available with a doctor's
prescription.

4. DESCRIPTION
Teicoplanin is a glycopeptide-antibiotic produced by Actinoplanes
teichomyceticus. It is presented as a sterile, pyrogen-free ivory white powder for
reconstitution with water for injection. It is freely soluble in water and on
reconstitution gives a clear solution
Mechanism of action
Inhibits the growth of susceptible organisms by inhibiting
polymerization of cell wall components in susceptible bacteria
INDICATIONS
▪ Tarocigd is indicated for the treatment of the following serious infections due to
staphylococci or :streptococci, which cannot be treated satisfactorily with less
toxic agents, including b-lactam antibiotics-
▪ Blood - non-cardiac bacteraemia, septicaemia
▪ Bone - osteomyelitis Joints - septic arthritis

5. Indications Loading dose Maintenance dose
- Complicated skin and soft tissue
infections
- Pneumonia
- Complicated urinary tract infections
400 mg intravenous or intramuscular
(this equates to approximately 6
mg/kg body weight) every 12 hours
for 3 administrations
>15 mg/L1
- Bone and joint infections 800 mg intravenous (this equates to
approximately 12 mg/kg body weight)
every 12 hours for 3 to 5
administrations
>20 mg/L1
- Infective endocarditis 800 mg intravenous (this equates to
approximately 12 mg/kg body weight)
every 12 hours for 3 to 5
administrations
30-40 mg/L1

6. PHARMACOKINETICS
Absorption
● is administered by parenteral route (intravenously or intramuscularly). After
intramuscular administration, the bioavailability of teicoplanin (as compared to
intravenous administration) is almost complete (90%)
Distribution
● The binding to human serum proteins ranges from 87.6 to 90.8% without any variation
in function of the teicoplanin concentrations. Teicoplanin is mainly bound to human
serum albumin.
● Teicoplanin distributed mainly in lung, myocardium and bone tissues .Teicoplanin does
not readily penetrate into the cerebrospinal fluid (CSF).
Biotransformation
● Unchanged form of teicoplanin is the main compound identified in plasma and urine,
indicating minimal metabolism. Two metabolites are formed probably by hydroxylation
and represents 2 to 3% of the administered dose.
Elimination
● Unchanged teicoplanin is mainly excreted by urinary route (80% within 16 days) while
2.7% of the administered dose is recovered in feces (via bile excretion) within 8 days
following administration.
● Teicoplanin is mainly excreted by renal mechanisms.

7. PRECAUTIONS
✓ Targocid should be administered with caution in patients known to be hypersensitive to
vancomycin since cross-hypersensitivity may occur. However, a history of the "Red Man
Syndrome" that can occur with vancomycin is not a contraindication to Targocid.
✓ Periodic haematological studies, and renal and liver function tests are advised during
prolonged treatment. Serial renal and auditory function tests should be undertaken in
the following circumstances:
✓ In patients receiving prolonged therapy.
✓ In patients with renal insufficiency.
✓ During concurrent and sequential use of other drugs which may have ototoxic or
nephrotoxic properties. These include aminoglycosides, amphotericin, cyclosporin,
cisplatin, frusemide and ethacrynic acid. However, there are no toxicity data on the
concurrent use of these drugs with Targocid.
Interactions
✓ Due to the potential for increased adverse effects, Targocid should be administered
with caution in patients receiving concurrent nephrotoxic or ototoxic drugs, such as
aminoglycosides, amphotericin B, cyclosporin and frusemide
✓ pregnancy and lactation
✓ Carcinogenesis and Mutagenesis

8. ADVERSE DRUG REACTIONS
✓ Blood and the lymphatic system
disorders
Leucopenia, thrombocytopenia, eosinophilia
Agranulocytosis, neutropenia
✓ Immune system disorders
✓ Anaphylactic reaction (anaphylaxis)
✓ Drug reaction with eosinophilia and
systemic symptoms (DRESS), anaphylactic
shock
✓ Nervous system disorders
✓ Dizziness, headache Seizures
✓ Ear and Labyrinth disorders
✓ Deafness, hearing loss (see section 4.4),
tinnitus, vestibular disorder
✓ Vascular disorders
✓ Phlebitis Thrombophlebitis
✓ Respiratory, thoracic and mediastinal
disorders
✓ Bronchospasm
✓ Gastrointestinal disorders
✓ Diarrhoea, vomiting, nausea
✓ Skin and subcutaneous tissue disorders
✓ Rash, erythema, pruritus
✓ Red man syndrome (e.g. Flushing of the
upper part of the body) .
✓ Toxic epidermal necrolysis, Stevens-
Johnson syndrome, erythema multiforme,
angioedema, dermatitis exfoliative,
urticaria
✓ Renal and Urinary disorders
✓ Blood creatinine increased Renal failure
(including renal failure acute)
✓ General disorders and administration
site conditions
✓ Pain, pyrexia Injection site abcess, chills
(rigors)

9. When you must not be given it
❖ Do not receive Targocid if you are allergic to it or any of the ingredients listed at
the end of this leaflet.
❖ Some symptoms of an allergic reaction include skin rash, itching, shortness of breath or
swelling of the face, lips or tongue, which may cause difficulty in swallowing or
breathing.
❖ Do not receive it if you are pregnant or intend to become pregnant.
❖ It may affect your developing baby if you are given it during pregnancy.
❖ Do not receive it if you are breastfeeding or planning to breastfeed.
❖ It is not known whether Targocid passes into breast milk.
❖ Do not receive it after the expiry date (EXP) printed on the pack or vial,
❖ If you receive it after the expiry date has passed, it may not work as well.
❖ Do not receive it if the package is damaged or shows signs of tampering.

10. Monitoring parameters
● Renal&Liver functional tests
● Plasma concentration
● Heamatological parameters
PATIENT COUNSELLING
Do not skip the dose
Aware of adverse drug reactions
Do not stop the drug without physician advise

11. REFERENCES
● WWW.Antimicrobe.org
● WWW.Drugs.com
● WWW.Drug bank